JPRN-UMIN000000795已完成2 期
A randomized controlled study comparing Anastrozole+TS-1 as postoperative chemotherapy in ER positive metastatic breast cancer - TS-1 and ANA combination therapy in Chugoku and Shikoku trial (TACS trial)
Department of Breast and Thyroid Surgery, Kawasaki Medical School0 个研究点目标入组 100 人开始时间: 2007年8月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) concomitant malignancy 2) patient with marked infection 3) patient with marked fever and suspected infection 4) patient with metastasis to CNS 5) complications including ischemic heart disease 6) Active gastrointestinal ulceration 7) Serious Neuropathy 8) Anarmnesis of drug allergy 9) Severe Bone marrow suppression 10) serious renal function disturbance 11) serious liver function disturbance 12) taking other fluoropyrimidine derivatives 13) Under treatment with flucytosine 14) Not suitable for participating in the study for any other reason
研究者
相似试验
进行中（未招募）
不适用
A randomised Phase II Study comparing anastrozole and fulvestrant to an-astrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone marrow - ABCSG 21postmenopausal women with hormone receptor positive early breast cancerEUCTR2005-005715-22-ATAstraZeneca AB176
进行中（未招募）
1 期
A randomised Phase II Study comparing anastrozole and fulvestrant to an-astrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone marrow - ABCSG 21EUCTR2005-005715-22-NOAstraZeneca AB176
进行中（未招募）
不适用
A randomised Phase II Study comparing anastrozole and fulvestrant to anastrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone marrow - ABCSG 21EUCTR2005-005715-22-DEAstraZeneca AB176
已完成
2 期
Randomized Phase II Trial of Anastrozole plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast CancerJPRN-UMIN000006434Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine120
进行中（未招募）
不适用
A phase III study comparing anastrozole, letrozole and exemestane, upfront (for 5 years) or sequentially (for 3 years after 2 years of tamoxifen), as adjuvant treatment of postmenopausal patients with endocrine-responsive breast cancer - GIM3- FATAadjuvant hormono-therapy in breast cancer patientsMedDRA version: 6.1Level: PTClassification code 10006279EUCTR2006-004018-42-ITIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II